Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Identification of novel IgE epitopes

An amino acid and sequence technology, applied in the field of identification of new IgE epitopes, can solve problems such as the risk of inducing allergic antibodies

Inactive Publication Date: 2007-03-07
TANOX
View PDF22 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Peptides used to generate anti-IgE antibodies also have the risk of inducing sensitizing antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Identification of novel IgE epitopes
  • Identification of novel IgE epitopes
  • Identification of novel IgE epitopes

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0107] Preparation of High Affinity Antibodies

[0108] Once the parent antibody has been identified and isolated, one or more amino acid residues in one or more variable regions of the parent antibody may be altered. Alternatively, one or more framework residues may be substituted in the parent antibody such that the binding affinity of the antibody, eg, for human IgE, is improved. Framework region residues to be modified include, for example, residues that bind non-covalently directly to the target (Amit et al. Science 233:747-753 (1986)); those that interact with / affect the conformation of the CDR (Chothia et al. J. Mol. Biol. 196:901-917 (1987)); and / or residues involved in the VL-VH interface (EP 239 400 B1 ). In certain embodiments, modification of one or more such framework region residues results in increased binding affinity of the antibody for the target of interest.

[0109] Modification of the biological properties of an antibody can be achieved by selecting subs...

Embodiment 1

[0202] Example 1: Humanization of anti-IgE murine MAb TES-C21

[0203] The heavy chain variable region (V H ) and the light chain variable region (V L ) were compared to human antibody germline sequences obtained from public databases. When deciding on a template as described in step 1 above, a number of criteria are used, including full length, similar CDR positions within the framework, overall homology, size of the CDRs, and the like. Considering all of these criteria holistically allows selection of the optimal human template, as shown in the sequence alignment between the TES-C21 MAb heavy and light chain sequences and representative human template sequences, shown in Figures 3A and 3B.

[0204] In this case, the antibody was designed using more than one human framework template. for V H The human template for chain selection was the combination of DP88 (amino acid residues 1-95) and JH4b (amino acid residues 103-113) (see Figure 3B). for V L The human template for ...

Embodiment 2

[0211] Example 2: V H and V L Cloned into phage expression vector

[0212] V H and V L Cloned into a phage expression vector. Uridylated templates were obtained by infecting CJ236 Escherichia coli strain (dut - ung - ) and prepared.

[0213] The following components [200ng uridine acidified phage vector (8.49kb); 92ng phosphorylated single chain H chain (489 bases); 100ng phosphorylated single chain L chain (525 bases); 1μL 10× annealing buffer, with ddH 2 O adjust the volume to 10 μL] Annealing was performed by PCR maintaining the temperature at 85° C. for 5 minutes (denaturation), followed by a gradient down to 55° C. over 1 hour (approximately 8-fold molar ratio of insert to vector). The samples were chilled on ice.

[0214] Add the following components to the annealed product: 1.4 μL 10× synthesis buffer, 0.5 μL T4 DNA ligase (1 unit / μL), 1 μL T4 DNA polymerase (1 unit / μL), and then incubate on ice for 5 minutes at 37 Incubate for 1.5 hours at °C. The product wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to novel peptide epitopes derived from the CH3 domain of IgE which are recognized by high affinity antibodies that specifically bind IgE. These novel peptides may be used for both active immunization of a subject by administering these peptides to generate high affinity antibodies in a subject, as well as for generating high affinity anti-IgE antibodies in non-human hosts that specifically bind to these regions of IgE for passive immunization of a subject.

Description

[0001] cross related application [0002] This application claims priority to PCT Applications PCT / US04 / 02892 and PCT / US04 / 02894, filed February 2, 2004, which are incorporated herein by reference. Background of the invention [0003] Allergy is an allergic state induced by an exaggerated immune response to exogenous factors such as allergens. Immediate hypersensitivity reactions (type I), characterized by an allergic reaction immediately following exposure to an allergen, are B cell-mediated and based on an antigen-antibody reaction. Delayed-type hypersensitivity is mediated by T cells and is based on cellular immune mechanisms. In recent years, the term "allergy" has increasingly become synonymous with type I hypersensitivity. [0004] Immediate hypersensitivity is a response based on the production of immunoglobulin E (IgE antibodies) by B cells that, upon exposure to an allergen, differentiate into antibody-secreting plasma cells. IgE-induced responses are local events ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K7/00C07K16/18A61K39/00
Inventor 桑贾亚·辛格黄丹阳锡·钟·迈克尔·冯
Owner TANOX
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com